Ypsomed Holding AGXSWX:YPSN -0.33%92 Return-on-Tangible-Equity is 26.00% as of Mar. 2026, which is 22% above its 10-year median of 21.28. GuruFocus rates XSWX:YPSN with a GF Score™ of 92/100 and a GF Value™ of CHF397.11 (Fairly Valued). The stock has 4 warning signs investors should review. Among 759 Medical Devices & Instruments companies, Ypsomed Holding AG ranks better than 91.04% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Ypsomed Holding AG's annualized net income for the quarter that ended in Mar. 2026 was CHF165.7 Mil. Ypsomed Holding AG's average shareholder tangible equity for the quarter that ended in Mar. 2026 was CHF637.3 Mil. Therefore, Ypsomed Holding AG's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 26.00%.
The historical rank and industry rank for Ypsomed Holding AG's Return-on-Tangible-Equity or its related term are showing as below:
XSWX:YPSN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 2.28 Med: 21.28 Max: 44.75
Current: 40.5
During the past 13 years, Ypsomed Holding AG's highest Return-on-Tangible-Equity was 44.75%. The lowest was 2.28%. And the median was 21.28%.
XSWX:YPSN's Return-on-Tangible-Equity is ranked better than 91.04% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.07
vs XSWX:YPSN: 40.50
Ypsomed Holding AG (XSWX:YPSN) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Ypsomed Holding AG Return-on-Tangible-Equity Related Terms
Ypsomed Holding AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Ypsomed Holding AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ypsomed Holding AG Return-on-Tangible-Equity Chart
XSWX:YPSN vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Ypsomed Holding AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ypsomed Holding AG Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ypsomed Holding AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Ypsomed Holding AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 26.00% mean?
Ypsomed Holding AG (XSWX:YPSN) has a Return-on-Tangible-Equity of 26.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ypsomed Holding AG and its competitors. This is 22% above median its historical median of 21.28. Over the past decade, Ypsomed Holding AG's Return-on-Tangible-Equity has ranged from 2.28 to 44.75. According to the industry distribution chart, Ypsomed Holding AG ranks #68 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 9%.
Is Ypsomed Holding AG's Return-on-Tangible-Equity too high?
Ypsomed Holding AG's current Return-on-Tangible-Equity of 26.00% is 22% above median its 10-year median of 21.28. Over the past 10 years, this metric has ranged from a low of 2.28 to a high of 44.75. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.07. Ypsomed Holding AG's value of 26.00% is 538.8% above this industry median. Based on the distribution chart, Ypsomed Holding AG ranks #68 out of 759 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Ypsomed Holding AG has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ypsomed Holding AG's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ypsomed Holding AG ranks #68 out of 759 companies for Return-on-Tangible-Equity. This places Ypsomed Holding AG in the top 9% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.07. Ypsomed Holding AG's value of 26.00% is 538.8% above this benchmark. Historically, Ypsomed Holding AG's own Return-on-Tangible-Equity has ranged from 2.28 to 44.75 over the past decade. While the company's 10-year median is 21.28 vs. the industry median of 4.07, Ypsomed Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.07, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ypsomed Holding AG's current Return-on-Tangible-Equity of 26.00% is 538.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ypsomed Holding AG and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ypsomed Holding AG's current Return-on-Tangible-Equity is 26.00%, which is 22% above median its own 10-year median of 21.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ypsomed Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Ypsomed Holding AG (XSWX:YPSN) is currently considered Fairly Valued. The stock's GF Value™ is CHF397.11, compared to a current price of CHF359.40 — trading 9.5% below its estimated fair value. The current Return-on-Tangible-Equity is 26.00%, which is 22% above median its 10-year median of 21.28 and 538.8% above the Medical Devices & Instruments industry median of 4.07. Ypsomed Holding AG's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Ypsomed Holding AG (XSWX:YPSN), the current Return-on-Tangible-Equity is 26.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ypsomed Holding AG (XSWX:YPSN) Overvalued in 2026?
Based on GuruFocus' analysis, Ypsomed Holding AG stock appears to be undervalued.
The current stock price of CHF359.40 is trading 9.5% below its estimated GF Value™ of CHF397.11.
GuruFocus considers Ypsomed Holding AG to be Fairly Valued.
Key valuation signals for XSWX:YPSN:
Return-on-Tangible-Equity: 26.00% (22% above median its 10-year median of 21.28)
GF Value™: CHF397.11 vs. price of CHF359.40 (9.5% below fair value)
Industry Position: 538.8% above the Medical Devices & Instruments median (#68 of 759)
No single metric tells the full story. See the XSWX:YPSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.
92GF Score
Get the complete analysis for XSWX:YPSN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:YPSN has been successfully added to your 
